NEW YORK (GenomeWeb News) – CombiMatrix announced this morning that it will collaborate with Clarient in marketing and selling CombiMatrix’s HemeScan, a prognostic and diagnostic monitoring tool, for chronic lymphocytic leukemia.
The test was developed by CombiMatrix in collaboration with researchers at the MD Anderson Cancer Center in Houston, the University of Texas Health Sciences Center in San Antonio, and the Netherlands Cancer Institute in Amsterdam.
Cancer diagnostics services lab Clarient will market the tests to pathologists, oncologists, and patients, under the agreement.
According to CombiMatrx, the test provides prognostic marker precision with simultaneous diagnostic monitoring of the entire genome in CLL. The firm said that the test also has been validated for acute lymphoblastic leukemia and myelodysplastic syndrome, and it is currently being tested for multiple myeloma.
CombiMatrix said there are more than 10,000 new cases of CLL annually in the US and over 150,000 patients living with the disease.